Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that predictable routine of meetings, deadlines, and the like has, indeed, returned. And of course, we are coping by quaffing cups of stimulation. As always, you are invited to join us. Firing up the neurons is not a bad thing, after all. And remember, no prescription is required. Meanwhile, here are some items of interest to help you along. Hope you have a smashing day and please do stay in touch …
GlaxoSmithKline (GSK) won another reprieve for its blockbuster Advair lung drug after the Food and Drug Administration insisted Hikma Pharmaceuticals (HIK) conduct a further clinical study evaluating its generic version of the drug, Reuters writes. Hikma expects to submit a response to the agency with new clinical data in 2019, which means a potential launch could come in 2020 if all goes well. Hikma already faced a delay for its generic last year, as did generic drug company Mylan. Last month, a third Advair copy from Novartis’s Sandoz division also got knocked back by the FDA.
About the Author Reprints
